Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity

Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects

(2017) Daisuke Ibi et al.   NATURE NEUROSCIENCE

Genetic insights into the neurodevelopmental origins of schizophrenia

(2017) Rebecca Birnbaum et al.   NATURE REVIEWS NEUROSCIENCE

Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation

(2017) Adam G Walker et al.   NEUROPSYCHOPHARMACOLOGY

Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort

(2017) Anja P. Husa et al.   PSYCHIATRY RESEARCH

Targeting metabotropic glutamate receptors for novel treatments of schizophrenia

(2017) James Maksymetz et al.   Molecular Brain

The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies

(2016) Madeleine Duvic et al.   CANCER TREATMENT REVIEWS

Epigenetic Mechanisms of Serotonin Signaling

(2015) Terrell Holloway et al.   ACS Chemical Neuroscience

Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials

(2015) R. E. Nielsen et al.   ACTA PSYCHIATRICA SCANDINAVICA

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

(2015) Bruce J. Kinon et al.   BIOLOGICAL PSYCHIATRY

Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects

(2015) Yasmin Schmid et al.   BIOLOGICAL PSYCHIATRY

Antipsychotics and Amotivation

(2015) Gagan Fervaha et al.   NEUROPSYCHOPHARMACOLOGY

Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction

(2015) Adam G. Walker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment

(2015) Amr Ellaithy et al.   TRENDS IN NEUROSCIENCES

Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage

(2015) Marta Motolese et al.   Molecular Brain

Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories

(2014) Johannes Gräff et al.   CELL

Epigenetic upregulation of metabotropic glutamate receptor 2 in the spinal cord attenuates oestrogen-induced visceral hypersensitivity

(2014) Dong-Yuan Cao et al.   GUT

Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex

(2014) Hong Geun Park et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia — An observational 9-year follow-up study

(2014) Anja P. Husa et al.   SCHIZOPHRENIA RESEARCH

mRNA expression profile of serotonin receptor subtypes and distribution of serotonergic terminations in marmoset brain

(2014) Rammohan Shukla et al.   Frontiers in Neural Circuits

The Potential of HDAC Inhibitors as Cognitive Enhancers

(2013) Johannes Gräff et al.   Annual Review of Pharmacology and Toxicology

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

(2013) David H Adams et al.   BMC Psychiatry

Preclinical models of antipsychotic drug action

(2013) José L. Moreno et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Update on Typical and Atypical Antipsychotic Drugs

(2012) Herbert Y. Meltzer   Annual Review of Medicine

Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents

(2012) S Miyamoto et al.   MOLECULAR PSYCHIATRY

An epigenetic blockade of cognitive functions in the neurodegenerating brain

(2012) Johannes Gräff et al.   NATURE

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity

(2012) Mitsumasa Kurita et al.   NATURE NEUROSCIENCE

Epigenetic protein families: a new frontier for drug discovery

(2012) Cheryl H. Arrowsmith et al.   NATURE REVIEWS DRUG DISCOVERY

Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs

(2011) Miguel Fribourg et al.   CELL

A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia

(2011) Bruce J. Kinon et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists

(2011) José L. Moreno et al.   NEUROSCIENCE LETTERS

Metabotropic glutamate receptors: From the workbench to the bedside

(2010) F. Nicoletti et al.   NEUROPHARMACOLOGY

Group II metabotropic glutamate receptors and schizophrenia

(2009) José L. Moreno et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Schizophrenia

(2009) Jim van Os et al.   LANCET

HDAC2 negatively regulates memory formation and synaptic plasticity

(2009) Ji-Song Guan et al.   NATURE

Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects

(2009) M. van den Buuse   SCHIZOPHRENIA BULLETIN

Psychedelics and schizophrenia

(2009) Javier González-Maeso et al.   TRENDS IN NEUROSCIENCES

Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039)

(2008) M. J. Fell et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Identification of a serotonin/glutamate receptor complex implicated in psychosis

(2008) Javier González-Maeso et al.   NATURE